Runben Biotechnology Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	168.56	185.77	106.59	243.83	368.21	206.19
Short-Term Investments	-	-	77.95	1,340	-	-
Trading Asset Securities	973.5	990.17	1,249	19	8.24	56.24
Cash & Short-Term Investments	1,142	1,176	1,434	1,603	376.45	262.43
Cash Growth	-17.61%	-17.97%	-10.57%	325.85%	43.45%	221.20%
Accounts Receivable	22.13	17.91	13.59	4.82	1.19	2.34
Other Receivables	5.64	4.24	4.62	2.32	6	9.8
Receivables	27.78	22.15	18.22	7.14	7.2	12.15
Inventory	187.23	120.59	118.57	92.91	102.71	56.9
Other Current Assets	338.56	321.34	24.43	13.16	23.68	12.89
Total Current Assets	1,696	1,640	1,595	1,716	510.04	344.36
Property, Plant & Equipment	300.54	295.88	267.57	260.42	277.56	207.67
Other Intangible Assets	86.8	87.32	54.54	18.76	19.36	19.88
Long-Term Deferred Tax Assets	54.58	50.43	44.23	20.82	14.8	5.66
Long-Term Deferred Charges	2.05	1.51	1.26	1.41	-	-
Other Long-Term Assets	292.23	262.61	256.9	1.13	3.65	68.77
Total Assets	2,432	2,338	2,219	2,019	825.42	646.34
Accounts Payable	104.22	61.16	53.8	40.15	36.99	46.37
Accrued Expenses	10.87	15.72	32.16	26.21	24.43	11.41
Current Portion of Long-Term Debt	1.06	1.42	-	-	-	-
Current Portion of Leases	-	-	1.37	1.95	2.51	2.4
Current Income Taxes Payable	22.38	16.23	26.29	15.47	18.28	5.29
Current Unearned Revenue	6.51	11.38	13.37	5.97	4.5	4.2
Other Current Liabilities	9.34	6.97	10.21	5.36	9.89	5.84
Total Current Liabilities	154.39	112.88	137.19	95.12	96.6	75.52
Long-Term Leases	-	-	1.42	2.04	5.39	7.91
Long-Term Unearned Revenue	3.61	3.78	0.01	0.01	0.27	1.13
Long-Term Deferred Tax Liabilities	0.21	0.13	0.27	0.44	0.57	0.14
Total Liabilities	158.21	116.79	138.88	97.61	102.83	84.69
Common Stock	404.59	404.59	404.59	404.59	343.9	343.9
Additional Paid-In Capital	1,015	1,015	1,015	1,015	102.59	101.69
Retained Earnings	853.84	801.2	660.67	502.12	276.09	116.05
Shareholders' Equity	2,274	2,221	2,080	1,921	722.59	561.65
Total Liabilities & Equity	2,432	2,338	2,219	2,019	825.42	646.34
Total Debt	1.06	1.42	2.78	4	7.91	10.31
Net Cash (Debt)	1,141	1,175	1,431	1,599	368.54	252.12
Net Cash Growth	-17.54%	-17.91%	-10.52%	333.90%	46.18%	208.59%
Net Cash Per Share	2.82	2.91	3.53	4.53	1.08	0.75
Filing Date Shares Outstanding	404.89	403.52	404.59	404.59	404.59	343.9
Total Common Shares Outstanding	404.89	403.52	404.59	404.59	343.9	343.9
Working Capital	1,541	1,527	1,458	1,621	413.44	268.84
Book Value Per Share	5.62	5.50	5.14	4.75	2.10	1.63
Tangible Book Value	2,187	2,134	2,026	1,903	703.22	541.76
Tangible Book Value Per Share	5.40	5.29	5.01	4.70	2.04	1.58
Buildings	-	-	231.94	232.54	231.65	163.47
Machinery	-	-	96.7	87.77	79.06	57.22
Construction In Progress	-	-	18.07	1.82	5.76	7.17

Source: S&P Global Market Intelligence. Standard template. Financial Sources.